Earticle

초록

영어

Purpose: Currently lung cancer ranks second in cancer for incidence rate and is a disease that ranks first for a deathrate by cancerous growth because it is already advanced at the time of diagnosis. The purpose of this paper was to ana-lyze the factors that affect the effectiveness of and rash occurrence by Epidermal Growth Factor Receptor TyrosineKinase Inhibitor (EGFR TKI) in patients with non-small cell lung cancer. Methods: A retrospective chart review of 100patients, who took EGFR TKI (erlotinib, gefitinib) among patients who were diagnosed with non-small cell lung can-cer in a Hospital in Korea between May 2005 and February 2008, was conducted. The drug effectiveness was evalu-ated by Response Evaluation Criteria In Solid Tumor. Results: EGFR mutation was the only factor associated with drugresponse (complete response and partial response). When stable disease was added to drug response as the evaluationparameter, ECOG and rash as well as EGFR mutation were found to be important factors. Survival, however, was notaffected by EGFR mutation. The factors influenced on survival were older age (≥65), low ECOG (1~2), adenocarci-noma and rash. In the case of rash, group with EGFR mutation or low ECOG showed significantly higher chance ofoccurrence. There was no significant difference in rash occurrence between gefitinib and erlotinib groups. Conclusions:Based on the results, EGFR mutation positive and low ECOG (1~2) were significantly important factors for both effec-tiveness of EGFR TKI and rash occurrence. Also, rash itself was found to be an independently significant factor for thedisease control and survival. Therefore, while administering EGFR TKI, patients who have the factors associated withrash occurrence should be closely monitored for effective and safe drug therapy.

목차

abstract
 연구 방법
  연구대상
  자료수집내용
  분석내용
  통계학적 분석
 연구 결과
 고 찰
 참고문헌

키워드

저자

• 배나래 [ Narae Bae | 이화여자대학교 임상보건과학대학원(Graduate School of Clinical Health Sciences, Ewha Womans University) ]
• 최혜진 [ Hyejin Choi | 연세대학교 의료원 종양내과(Department of Cancer Clinic, Yonsei University Medical Center) ]
• 이병구 [ Byungkoo Lee | 이화여자대학교 약학대학(College of Pharmacy, Ewha Womans University) ]
• 곽혜선 [ Hyesun Gwak | 이화여자대학교 약학대학(College of Pharmacy, Ewha Womans University) ] Correspondence

참고문헌

발행기관

간행물

표지보기 관심저널 등록

• 간행물명

  한국임상약학회지 [Korean Journal of Clinical Pharmacy]

• 간기

  계간

• pISSN

  1226-6051

• 수록기간

  1991~2026

• 등재여부

  KCI 등재

• 십진분류

  KDC 518 DDC 615